Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Although the deleterious vasoconstrictive effects of cell-free, hemoglobin-based blood substitutes have been appreciated, the systemic effects of chronic hemolysis on nitric oxide bioavailability have not been considered or quantified. Central to this investigation is the understanding that nitric oxide reacts at least 1,000 times more rapidly with free hemoglobin solutions than with erythrocytes. We hypothesized that decompartmentalization of hemoglobin into plasma would divert nitric oxide from homeostatic vascular function. We demonstrate here that plasma from patients with sickle-cell disease contains cell-free ferrous hemoglobin, which stoichiometrically consumes micromolar quantities of nitric oxide and abrogates forearm blood flow responses to nitric oxide donor infusions. Therapies that inactivate plasma hemoglobin by oxidation or nitric oxide ligation restore nitric oxide bioavailability. Decompartmentalization of hemoglobin and subsequent dioxygenation of nitric oxide may explain the vascular complications shared by acute and chronic hemolytic disorders.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Priapism, nephropathy, and sickle vasculopathy are associated with hemolysis.”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [59]
In the citing paper
“In these complications HbF has a less obvious beneficial effect, perhaps because only a small number of lysed sickle erythrocytes are needed to trigger these subphenotypes.59”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [59]
In the citing paper
“As HbF falls and fewer F-cells are protected from HbS polymer damage, the propensity for vascular occlusion and intravascular hemolysis increases with the release of heme products into the circulation that scavenge nitric oxide causing endothelial damage and vasculopathy.[57][58][59]”
From Fetal hemoglobin in sickle cell anemia (2020) · cites this paper as [59]
In the citing paper
“A further consequence of sickling of cells is increased RBC hemolysis. Hemolysis affects not only the number of circulating RBCs but also release of Hb (and other cytoplasmic proteins) within the blood stream, thus profoundly affecting the viscosity and colloid properties of plasma and increasing systemic NO scavenging (71, 152).”
From Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia (2017) · cites this paper as [152]
In the citing paper
“For example, in hemolytic anemia, release of free Hb may lead to systemic NO scavenging, affecting vascular tone (71, 152).”
From Red Blood Cell Function and Dysfunction: Redox Regulation, Nitric Oxide Metabolism, Anemia (2017) · cites this paper as [152]
Citations
Cites
De Caterina, R., Libby, P., Peng, H. B., Thannickal, V. J., Rajavashisth, T. B., Gimbrone, M. A., Shin, W. S., & Liao, J. K. (1995) · Journal of Clinical Investigation · doi:10.1172/jci118074 · Cited by 1,782
Identification of the haemoglobin scavenger receptor
Kristiansen, M., Graversen, J. H., Jacobsen, C., Sonne, O., Hoffman, H.-J., Law, S. K. A., & Moestrup, S. K. (2001) · Nature · doi:10.1038/35051594 · Cited by 1,712
Mechanism of NO-induced oxidation of myoglobin and hemoglobin
Eich, R. F., Li, T., Lemon, D. D., Doherty, D. H., Curry, S. R., Aitken, J. F., Mathews, A. J., Johnson, K. A., Smith, R. D., Phillips, et al. (1996) · Biochemistry · doi:10.1021/bi960442g · Cited by 613
Diffusion-limited reaction of free nitric oxide with erythrocytes
Liu, X., Miller, M. J. S., Joshi, M. S., Sadowska-Krowicka, H., Clark, D. A., & Lancaster, J. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.30.18709 · Cited by 512
A Tutorial on the Diffusibility and Reactivity of Free Nitric Oxide
Lancaster, J. R. (1997) · Nitric Oxide · doi:10.1006/niox.1996.0112 · Cited by 495
Nitric oxide in the human respiratory cycle
McMahon, T. J., Moon, R. E., Luschinger, B. P., Carraway, M. S., Stone, A. E., Stolp, B. W., Gow, A. J., Pawloski, J. R., Watke, P., Singel, D. J., et al. (2002) · Nature Medicine · doi:10.1038/nm718 · Cited by 469
Gladwin, M. T., Shelhamer, J. H., Schechter, A. N., Pease-Fye, M. E., Waclawiw, M. A., Panza, J. A., Ognibene, F. P., & Cannon, R. O. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.21.11482 · Cited by 441
Self-citationRate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin
Doherty, D. H., Doyle, M. P., Curry, S. R., Vali, R. J., Fattor, T. J., Olson, J. S., & Lemon, D. D. (1998) · Nature Biotechnology · doi:10.1038/nbt0798-672 · Cited by 432
Autoxidation kinetics of aqueous nitric oxide
Ford, P. C., Wink, D. A., & Stanbury, D. M. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81748-o · Cited by 419
Research works printed but not linked: 3
- Vaughn, M.W., Kuo, L. & Liao, J.C. Effective diffusion distance of nitric oxide in the microcirculation. Am. J. Physiol. 274, H1705–H1714 (1998).
- Vogel, W.M., Dennis, R.C., Cassidy, G., Apstein, C.S. & Valeri, C.R. Coronary constrictor effect of stroma-free hemoglobin solutions. Am. J. Physiol. 251, H413–H420 (1986).
- Pohl, U. & Lamontagne, D. Impaired tissue perfusion after inhibition of endothelium-derived nitric oxide. Basic Res. Cardiol. 86, 97–105 (1991).
Cited by
Items 201–300 of 1,000
Belcher, J. D., Chen, C., Nguyen, J., Abdulla, F. A., Zhang, P., Nguyen, H. V., Nguyen, P., Killeen, T. F., Miescher, S., Brinkman, N. J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196455 · Cited by 120
Morris, C. R., Gladwin, M. T., & Kato, G. J. (2008) · Current Molecular Medicine · doi:10.2174/156652408786241447 · Cited by 124
“Although NO synthase expression and activity is increased [101], SCD is characterized by a state of NO resistance and increased NO inactivation [21, 102, 103].”
BackgroundInfluentialSelf-citationCritical Reviews: How we treat sickle cell patients with leg ulcers
Minniti, C. P., & Kato, G. J. (2015) · American Journal of Hematology · doi:10.1002/ajh.24134 · Cited by 121
Checchia, P. A., Bronicki, R. A., Muenzer, J. T., Dixon, D. J., RAITHEL, S. C., Gandhi, S. K., & Huddleston, C. B. (2012) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2012.09.100 · Cited by 116
Ambrusko, S. J., Gunawardena, S. W., Sakara, A., Windsor, B., Lanford, L. M., Michelson, P. H., & Krishnamurti, L. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20791 · Cited by 115
Heme Cytotoxicity and the Pathogenesis of Immune-Mediated Inflammatory Diseases
Larsen, R., Gouveia, Z., Soares, M. P., & Gozzelino, R. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00077 · Cited by 112
“Sickle cell anemia is also associated with tissue Fe overload, presumably driven by chronic accumulation of free heme in the circulation (Hebbel et al., 1988; Reiter et al., 2002).”
BackgroundAliyu, Z. Y., Kato, G. J., Taylor, J. G., Babadoko, A., Mamman, A. I., Gordeuk, V. R., & Gladwin, M. T. (2007) · American Journal of Hematology · doi:10.1002/ajh.21057 · Cited by 127
“This is a scavenging or inactivation reaction, because the vasodilator NO is oxidized to the inert nitrate (NO3 (2)) [12,13].”
BackgroundSelf-citationBallas, S. K., & Marcolina, M. J. (2006) · Transfusion · doi:10.1111/j.1537-2995.2006.00679.x · Cited by 114
“Recent studies suggest that hemolysis is a major determinant of certain complications of SS owing to its effects on nitric oxide (NO) bioavailability.(8) A role for hemolysis in reducing NO bioavailability and promoting endothelial dysfunction has been suggested by Reiter and associates(8) and proposed to contribute t…”
BackgroundEberhardt, R. T., McMahon, L., Duffy, S. J., Steinberg, M. H., Perrine, S. P., Loscalzo, J., Coffman, J. D., & Vita, J. A. (2003) · American Journal of Hematology · doi:10.1002/ajh.10387 · Cited by 113
“[8] suggested diminished NO bioavailability in HbSS.”
BackgroundCardiopulmonary Complications of Sickle Cell Disease: Role of Nitric Oxide and Hemolytic Anemia
Gladwin, M. T., & Kato, G. J. (2005) · Hematology · doi:10.1182/asheducation-2005.1.51 · Cited by 111
Self-citationErythroid DAMPs drive inflammation in SCD
Gladwin, M. T., & Ofori-Acquah, S. F. (2014) · Blood · doi:10.1182/blood-2014-03-563874 · Cited by 113
“Upstream NO reactions with oxyhemoglobin potently scavenge NO and inhibit its signaling.(2)”
Self-citationInorganic nitrite therapy: historical perspective and future directions
Kevil, C. G., Kolluru, G. K., Pattillo, C. B., & Giordano, T. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.04.042 · Cited by 113
Erythrocyte Hemolysis and Hemoglobin Oxidation Promote Ferric Chloride-induced Vascular Injury
Woollard, K. J., Sturgeon, S., Chin-Dusting, J. P. F., Salem, H. H., & Jackson, S. P. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m809095200 · Cited by 112
Sickle Cell Disease, Vasculopathy, and Therapeutics
Kassim, A. A., & DeBaun, M. R. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-120611-143127 · Cited by 122
Oxidant Stress and Haemolysis of the Human Erythrocyte
Sivilotti, M. L. A. (2004) · Toxicological Reviews · doi:10.2165/00139709-200423030-00004 · Cited by 113
Hemolysis‐Associated Pulmonary Hypertension in Thalassemia
MORRIS, C. R., KUYPERS, F. A., KATO, G. J., LAVRISHA, L., LARKIN, S., SINGER, T., & VICHINSKY, E. P. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.058 · Cited by 112
Meyer, C. G., Heiß, C., Drexhage, C., Kehmeier, E. S., Balzer, J., Mühlfeld, A., Merx, M. W., Lauer, T., Kühl, H. P., Floege, J., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.068 · Cited by 118
Role of Heme in Cardiovascular Physiology and Disease
Sawicki, K. T., Chang, H., & Ardehali, H. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.114.001138 · Cited by 121
“One of the pathogenic factors is thought to be the increased circulating ferrous heme and hemoglobin that scavenge NO, a potent vasodilator, in these patients.(47,85) Interestingly, hemoglobin protects bacteria against NO toxicity by catalyzing the dioxygenation of NO to nitrate.”
PULMONARY HYPERTENSION IN SICKLE CELL DISEASE: Relevance to Children
Kato, G. J., Onyekwere, O. C., & Gladwin, M. T. (2007) · Pediatric Hematology and Oncology · doi:10.1080/08880010601185892 · Cited by 110
“This hemoglobin reacts with NO in a rapid, nearly diffusion-limited reaction to produce methemoglobin and inert nitrate [29].”
BackgroundSelf-citationPathophysiology and therapy for haemoglobinopathies; Part I: sickle cell disease
Madigan, C., & Malik, P. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406010659 · Cited by 106
Loss of red cell chemokine scavenging promotes transfusion-related lung inflammation
Mangalmurti, N. S., Xiong, Z., Hulver, M., Ranganathan, M., Liu, X. H., Oriss, T. B., Fitzpatrick, M. E., Rubin, M. A., Triulzi, D. J., Choi, A. M. K., et al. (2008) · Blood · doi:10.1182/blood-2008-07-166264 · Cited by 111
Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria
Brodsky, R. A. (2007) · Blood Reviews · doi:10.1016/j.blre.2007.10.002 · Cited by 110
Tebbi, C. K. (2022) · Hemato · doi:10.3390/hemato3020024 · Cited by 138
“This is as a result of direct scavenging reactions due to cell-free plasma hemoglobin, limiting nitric oxide bioavailability and defective generation of this agent which is related to enzymatic consumption of arginine by erythrocyte arginase [29,30].”
BackgroundBrodsky, R. A. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-8-200804150-00003 · Cited by 110
“Many clinical manifestations of PNH are readily explained by hemoglobin-mediated nitric oxide scavenging after free hemoglobin is released from hemolyzed cells (31, 32).”
BackgroundNitric oxide metabolites induced in Anopheles stephensi control malaria parasite infection
Peterson, T. M. L., Gow, A. J., & Luckhart, S. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.10.037 · Cited by 126
“All reactions of UNO with Hb in the vasculature are decreased by the red blood cell (RBC) membrane [37], as UNO reacts at least 1000 times faster with free Hb than with Hb contained by the RBC membrane [38].”
BackgroundPlatelet Inhibition by Nitrite Is Dependent on Erythrocytes and Deoxygenation
Srihirun, S., Sriwantana, T., Unchern, S., Kittikool, D., Noulsri, E., Pattanapanyasat, K., Fucharoen, S., Piknova, B., Schechter, A. N., & Sibmooh, N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030380 · Cited by 109
“In the presence of cell-free hemoglobin, the effect of nitrite on platelets was abolished because nitrite reacted rapidly with free hemoglobin to form the inactive nitrate ions [12].”
BackgroundSelf-citationEffect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice
Kaul, D. K., Liu, X.-D., Chang, H.-Y., Nagel, R. L., & Fabry, M. E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421633 · Cited by 110
“In sickle cell disease, increased oxidative stress (10) and systemic effects of chronic hemolysis (15) both may contribute to NO inactivation.”
BackgroundInfluentialAliyu, Z. Y., Gordeuk, V., Sachdev, V., Babadoko, A., Mamman, A. I., Akpanpe, P., Attah, E., Suleiman, Y., Aliyu, N., Yusuf, J., et al. (2008) · American Journal of Hematology · doi:10.1002/ajh.21162 · Cited by 105
“Hemolysis associated with malaria produces a similar state of endothelial dysfunction secondary to NO scavenging by cell free hemoglobin and plasma arginase as that seen in SCD [7,9].”
Self-citationHaptoglobin Preserves Vascular Nitric Oxide Signaling during Hemolysis
Schaer, C. A., Deuel, J., Schildknecht, D., Mahmoudi, L., García‐Rubio, I., Owczarek, C. M., Schauer, S., Kissner, R., Banerjee, U., Palmer, A. F., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201510-2058oc · Cited by 113
Barnett, C. F., Hsue, P. Y., & Machado, R. F. (2008) · JAMA · doi:10.1001/jama.299.3.324 · Cited by 117
Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein
Nielsen, M. J., Petersen, S. V., Jacobsen, C., Oxvig, C., Rees, D., Møller, H. J., & Moestrup, S. K. (2006) · Blood · doi:10.1182/blood-2006-05-022327 · Cited by 107
Association between haptoglobin, hemopexin and mortality in adults with sepsis
Janz, D. R., Bastarache, J. A., Sills, G., Wickersham, N., May, A. K., Bernard, G. R., & Ware, L. B. (2013) · Critical Care · doi:10.1186/cc13108 · Cited by 109
“Morbidity may be mediated in these conditions by the ability of cell-free hemoglobin to scavange nitric oxide in various vascular beds [10-14], damage the vascular endothelium [15], activate neutrophils [16], and oxidize lipid membranes via redox cycling [7,17].”
BackgroundSetty, Y. B. N., Betal, S. G., ZHANG, J., & Stuart, M. J. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03177.x · Cited by 116
“Erythrocytes, that undergo hemolysis intravascularly, release heme and hemoglobin into the circulation with documented studies suggesting that both heme and cell-free hemoglobin may modulate disease severity in patients with SCD by decreasing the bio-availability of the cyto-protective mediator nitric oxide (NO) [10-1…”
BackgroundHsu, L. L., Miller, S. T., Wright, E., Kutlar, A., McKie, V., Wang, W., Pegelow, C. H., Driscoll, C., Hurlet, A., Woods, G., et al. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200308000-00007 · Cited by 103
“In addition, concomitant alpha thalassemia-2 decreases hemolysis in sickle cell disease,(11,19) and there is considerable evidence that free Hb is toxic to endothelial cells and scavenges nitric oxide.(38) We speculate that plasma Hb may be lower in sickle cell patients with concomitant alpha thalassemia-2, and that t…”
BackgroundWang, Q., & Zennadi, R. (2021) · Antioxidants · doi:10.3390/antiox10101608 · Cited by 119
The Perfusion Paradox and Vascular Instability in Sickle Cell Disease
NATH, K. A., KATUSIC, Z. S., & GLADWIN, M. T. (2004) · Microcirculation · doi:10.1080/10739680490278592 · Cited by 102
“This inhibition of NO will impair important vascular functions of NO, such as vasodilation, platelet inhibition, and the tonic downregulation of VCAM-1 and E-selectin (96,97).”
BackgroundSelf-citationOlsson, M. G., Centlow, M., Rutardóttir, S., Stenfors, I., Larsson, J., Hosseini‐Maaf, B., Olsson, M. L., Hansson, S. R., & Åkerström, B. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.10.052 · Cited by 111
“Heme and ROS may cause further oxidation and membrane damage [7-9 , 26 Cell-free Hb is also a scavenger of nitric oxide (NO) [44], and may thus contribute to some of the vasoconstriction and hypertension observed in PE.”
InfluentialHydroxyurea and Arginine Therapy: Impact on Nitric Oxide Production in Sickle Cell Disease
Morris, C. R., Vichinsky, E. P., van Warmerdam, J., Machado, L., Kepka‐Lenhart, D., Morris, S. M., & Kuypers, F. A. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200308000-00008 · Cited by 102
“Decreased NO bioavailability plays a significant role in the pathophysiology of SCD.39 It has recently been recognized that scavenging of NO by elevated cell-free hemoglobin is one mechanism by which NO bioavailability is limited in SCD.40 This, in turn, could lead to increased Arg metabolism in a compensatory attempt…”
BackgroundInfluentialThromboinflammatory mechanisms in sickle cell disease - challenging the hemostatic balance
Conran, N., & Paula, E. V. D. (2020) · Haematologica · doi:10.3324/haematol.2019.239343 · Cited by 109
“Intravascular hemolysis is now widely accepted as a major pro-inflammatory mechanism that significantly influences the pathophysiology of numerous diseases and disorders, including SCD.(4) As previously mentioned, the reaction of cell-free hemoglobin, released during hemolysis, with vascular NO incurs immediate effect…”
BackgroundAscorbate removes key precursors to oxidative damage by cell-free haemoglobin in vitro and in vivo
Dunne, J., Caron, A., Menu, P., Alayash, A. I., Buehler, P. W., Wilson, M. T., Silaghi-Dumitrescu, R. L., Faivre, B., & Cooper, C. E. (2006) · Biochemical Journal · doi:10.1042/bj20060341 · Cited by 111
Pathophysiologically based drug treatment of sickle cell disease
Steinberg, M. H. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.02.007 · Cited by 101
Helley, D., de Latour, R. P., Porcher, R., Rodrigues, C. A., Galy–Fauroux, I., Matheron, J., Duval, A., Schved, J., Fischer, A., Socié, G., et al. (2010) · Haematologica · doi:10.3324/haematol.2009.016121 · Cited by 102
Cerebrovascular disease associated with sickle cell pulmonary hypertension
Kato, G. J., Hsieh, M., Machado, R., Taylor, J., Little, J., Butman, J. A., Lehky, T., Tisdale, J., & Gladwin, M. T. (2006) · American Journal of Hematology · doi:10.1002/ajh.20642 · Cited by 100
Self-citationOlsson, M. G., Allhorn, M., Bülow, L., Hansson, S. R., Ley, D., Olsson, M. L., Schmidtchen, A., & Åkerström, B. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2011.4282 · Cited by 105
“This has been described in, for example, sickle cell disease (239) and PE (218) (see also below).”
Pecker, L. H., & Lanzkron, S. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202101190 · Cited by 112
Hemolysis Derived Products Toxicity and Endothelium: Model of the Second Hit
Frimat, M., Boudhabhay, I., & Roumenina, L. T. (2019) · Toxins · doi:10.3390/toxins11110660 · Cited by 107
“Capturing NO produced by ECs, oxyHb inhibits its paracrine diffusion into vascular smooth muscle cells and alters vasomotricity [28,107].”
BackgroundMethodArginine, nitric oxide, carbon monoxide, and endothelial function in severe malaria
Weinberg, J. B., Lopansri, B. K., Mwaikambo, E. D., & Granger, D. L. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32830ef5cf · Cited by 105
Sickle‐cell disease and the heart: review of the current literature
Voskaridou, E., Christoulas, D., & Terpos, E. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09143.x · Cited by 132
“…L-arginine, reducing NO bioavailability, 668 ª 2012 Blackwell Publishing Ltd British Journal of Haematology, 2012, 157, 664–673 particularly in those patients with the highest haemolytic rate, and correlating with PH and early mortality (Reiter et al, 2002; Gladwin et al, 2004; Morris et al, 2005).”
BackgroundAnalysis and clinical relevance of microparticles from red blood cells
Tissot, J., Rubin, O., & Canellini, G. (2010) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32833ec217 · Cited by 106
Cell-free hemoglobin: a novel mediator of acute lung injury
Shaver, C. M., Upchurch, C. P., Janz, D. R., Grove, B. S., Putz, N. D., Wickersham, N. E., Dikalov, S., Ware, L. B., & Bastarache, J. A. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00155.2015 · Cited by 101
“HEMOLYSIS LEADS TO ELEVATED plasma (PL) levels of cell-free hemoglobin (CFH) in several clinical conditions including sepsis, hemodialysis, sickle cell crisis, and extracorporeal circulation, and after red blood cell transfusion (9, 26, 32, 43, 46, 50, 64, 65).”
BackgroundRedox-dependent impairment of vascular function in sickle cell disease
Aslan, M., & Freeman, B. Α. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.08.014 · Cited by 102
Schaer, D. J., & Buehler, P. W. (2013) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a013433 · Cited by 96
“The NO depletion hypothesis is based on the findings that plasma from patients with SCD had elevated levels of free Hb, and accordingly, that the plasma from these patients had higher ex vivo NO-depleting activity (Reiter et al. 2002).”
BackgroundMassive transfusion and blood product use in the pediatric trauma patient
Dehmer, J. J., & Adamson, W. T. (2010) · Seminars in Pediatric Surgery · doi:10.1053/j.sempedsurg.2010.07.002 · Cited by 96
Kato, G. J., Wang, Z., Machado, R. F., Blackwelder, W. C., Taylor, J. G., & Hazen, S. L. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07658.x · Cited by 100
Zorca, S. M., Freeman, L. A., Hildesheim, M. E., Allen, D. T., Remaley, A. T., Taylor, J. G., & Kato, G. J. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08109.x · Cited by 107
“Chronic haemolysis, another pathological feature of SCD drawing increased attention, gives rise to diminished bioavailability of nitric oxide (NO), oxidant stress and endothelial activation (Kaul et al, 2000; Nath et al, 2000; Aslan et al, 2001; Reiter et al, 2002; Kato et al, 2006).”
BackgroundRBC NOS: regulatory mechanisms and therapeutic aspects
Özüyaman, B., Grau, M., Kelm, M., Merx, M. W., & Kleinbongard, P. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.05.002 · Cited by 95
Real time and in vivo monitoring of nitric oxide by electrocehmical sensors- From dream to reality
Zhang, X. (2004) · Frontiers in bioscience · doi:10.2741/1492 · Cited by 95
Shang, H., Xu, H., Jin, L., Wang, C., Chen, C., Song, T., & Du, Y. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112202 · Cited by 94
Evidence for a metabolic shift of arginine metabolism in sickle cell disease
Schnog, J. B., Jager, E. H., van der Dijs, F. P. L., Duits, A. J., Moshage, H. J., Muskiet, F. D., & Muskiet, F. A. J. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0856-9 · Cited by 101
“The higher the hemolytic rate, the more free hemoglobin circulates, which is known to induce endothelial activation and reduce NO bioavailability, also implicating that the comparable NOx levels between our patients and controls are not synonymous with comparable NO bioavailability [17, 25].”
BackgroundHydroxyurea induces the eNOS-cGMP pathway in endothelial cells
Čokić, V. P., Beleslin‐Čokić, B. B., Tomić, M., Stojilković, S. S., Noguchi, C. T., & Schechter, A. N. (2006) · Blood · doi:10.1182/blood-2005-11-4454 · Cited by 99
Yu, B., Shahid, M., Egorina, E. M., Sovershaev, M. A., Raher, M. J., Lei, C., Wu, M. X., Bloch, K. D., & Zapol, W. M. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181cd7838 · Cited by 93
“Indeed, hem- orrhagic shock alone produces endothelial dysfunction in animal models.17 In the future, HBOCs should be studied in animal models of endothelial dysfunction, because reduced vascular nitric oxide levels seem to sensitize these animals (and presumably humans) to the adverse effects of HBOCs.”
BackgroundInfluentialComputation of plasma hemoglobin nitric oxide scavenging in hemolytic anemias
Jeffers, A. B., Gladwin, M. T., & Kim‐Shapiro, D. B. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2006.08.017 · Cited by 100
Self-citationHebbel, R. P., Vercellotti, G. M., & Nath, K. A. (2009) · Cardiovascular & Haematological Disorders - Drug Targets · doi:10.2174/1871529x10909040271 · Cited by 102
“Alternatively, NO can be limited by its enhanced consumption, which occurs in sickle disease due to the activity of cell-free plasma hemoglobin; evidence is strong that the amounts of free hemoglobin in sickle plasma are, indeed, high enough to exert this effect [24].”
Haptoglobin Therapeutics and Compartmentalization of Cell-Free Hemoglobin Toxicity
Buehler, P. W., Humar, R., & Schaer, D. J. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.02.004 · Cited by 95
Obrador, R., Musulin, S. E., & Hansen, B. D. (2014) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/vec.12252 · Cited by 101
Adisa, O. A., Hu, Y., Ghosh, S., Aryee, D., Osunkwo, I., & Ofori‐Acquah, S. F. (2013) · British Journal of Haematology · doi:10.1111/bjh.12445 · Cited by 88
Schaer, D. J., Alayash, A. I., & Buehler, P. W. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1576 · Cited by 89
“First, patients with sickle cell disease—a hereditary chronic hemolytic disease—develop severe pulmonary hypertension that responds to treatment with inhaled NO (11, 38).”
Lezcano, N. E., Odo, N., Kutlar, A., Brambilla, D. J., & Adams, R. J. (2006) · Stroke · doi:10.1161/01.str.0000221173.97108.01 · Cited by 88
The Not-So-Simple Process of Sickle Cell Vasoocclusion
Embury, S. H. (2004) · Microcirculation · doi:10.1080/10739680490278277 · Cited by 95
“The apparent limited bioavailability of NO in sickle cell disease may be related to depleted stores of the NO precursor L-arginine (62), sequestering of NO in the plasma by free hemoglobin engendered by hemolysis (69), oxidative destruction of NO (4), or increased levels of arginase (63).”
BackgroundReversal of hemoglobin-induced vasoconstriction with sustained release of nitric oxide
Cabrales, P., Han, G., Nacharaju, P., Friedman, A. J., & Friedman, J. M. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00665.2010 · Cited by 86
Asthma management: Reinventing the wheel in sickle cell disease
Morris, C. R. (2009) · American Journal of Hematology · doi:10.1002/ajh.21359 · Cited by 87
“Despite an increase in NOS, NO bioavailability is low due to low substrate availability [55], NO scavenging by cell-free hemoglobin released during hemolysis [73], and through reactions with free radicals such as superoxide and other reactive NO species [74–76].”
BackgroundWood, K. C., Hebbel, R. P., Lefer, D. J., & Granger, D. N. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.12.015 · Cited by 91
Setty, Y. B. N., & Betal, S. G. (2007) · Blood · doi:10.1182/blood-2007-07-099465 · Cited by 89
Ergul, S., Brunson, C. Y., Hutchinson, J., Tawfik, A. M., Kutlar, A., Webb, R. C., & Ergul, A. (2004) · American Journal of Hematology · doi:10.1002/ajh.20107 · Cited by 86
“Recent studies also identified elevated cell-free Hb resulting from increased hemolysis in SCD as an important modulator of NO and vascular function [12,13].”
InfluentialGladwin, M. T. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29807 · Cited by 85
Self-citationErythrocytes as a preferential target of oxidative stress in blood
Fujii, J., Homma, T., Kobayashi, S., Warang, P. P., Madkaikar, M. R., & Mukherjee, M. B. (2021) · Free Radical Research · doi:10.1080/10715762.2021.1873318 · Cited by 92
“limiting the bioavailability of NO [50].”
Evolution of Novel Small-Molecule Therapeutics Targeting Sickle Cell Vasculopathy
Kato, G. J. (2008) · JAMA · doi:10.1001/jama.2008.598 · Cited by 85
Gordeuk, V. R., Minniti, C. P., Nouraie, M., Campbell, A. D., Rana, S. R., Luchtman-Jones, L., Sable, C., Dham, N., Ensing, G., Prchal, J. T., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.030767 · Cited by 84
“This is consistent with our previous model based on biochemical evidence of nitric oxide scavenging by plasma hemoglobin and arginine depletion by plasma arginase, plasma hemoglobin and arginase being products of intravascular red blood cell breakdown.(5,6) The additional finding that elevated E/Etdi ratio was an inde…”
ResultSelf-citationThe multifaceted role of ischemia/reperfusion in sickle cell anemia
Hebbel, R. P., Belcher, J. D., & Vercellotti, G. M. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133639 · Cited by 88
NO Contest: Nitrite Versus S -Nitroso-Hemoglobin
Gladwin, M. T., & Schechter, A. N. (2004) · Circulation Research · doi:10.1161/01.res.0000126697.64381.37 · Cited by 89
Self-citationRed Blood Cell Microparticles: Clinical Relevance
Rubin, O., Canellini, G., Delobel, J., Lion, N., & Tissot, J. (2012) · Transfusion Medicine and Hemotherapy · doi:10.1159/000342228 · Cited by 95
Pulmonary Hypertension in Sickle Cell Disease: Mechanisms, Diagnosis, and Management
Castro, O. L., & Gladwin, M. T. (2005) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2005.07.007 · Cited by 87
Self-citationHopp, M.-T., Schmalohr, B. F., Kühl, T., Detzel, M. S., Wißbrock, A., & Imhof, D. (2020) · Analytical Chemistry · doi:10.1021/acs.analchem.0c00415 · Cited by 84
Bad Blood: The risks of red cell storage
Lee, J. S., & Gladwin, M. T. (2010) · Nature Medicine · doi:10.1038/nm0410-381 · Cited by 83
Self-citationKaul, D. K., Zhang, X., Dasgupta, T., & Fabry, M. E. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00162.2008 · Cited by 80
“An important finding of the present studies with implications for NO bioavailability is the pronounced 50% decrease in cell-free plasma hemoglobin in arginine-treated BERK mice (see Table 1), which is expected to reduce NO inactivation by cell-free ferrous (oxy) hemoglobin (36).”
BackgroundInfluentialOxygenating the microcirculation: the perspective from blood transfusion and blood storage
Raat, N. J. H., & İnce, C. (2007) · Vox Sanguinis · doi:10.1111/j.1423-0410.2007.00909.x · Cited by 83
Patel, N. N., Gonsalves, C. S., Malik, P., & Kalra, V. K. (2008) · Blood · doi:10.1182/blood-2007-12-130567 · Cited by 82
Effect of Blood Nitrite and Nitrate Levels on Murine Platelet Function
Park, J. W., Piknova, B., Huang, P. L., Noguchi, C. T., & Schechter, A. N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055699 · Cited by 82
“Inorganic anions, nitrate (NO3 (2)) and nitrite (NO2 (2)), once considered inert end products from NO generation, can be reduced to NO by nonenzymatic as well as enzymatic pathways [8,9,10,11,12,13].”
BackgroundSelf-citationVasculature and Kidney Complications in Sickle Cell Disease
Nath, K. A., & Katušić, Z. S. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011101019 · Cited by 84
Almeida, C. B., Souza, L. E. B., Leonardo, F. C., Costa, F. T. M., Werneck, C. C., Covas, D. T., Costa, F. F., & Conran, N. (2015) · Blood · doi:10.1182/blood-2014-12-616250 · Cited by 82
Pulmonary arterial hypertension
Raiesdana, A., & Loscalzo, J. (2006) · Annals of Medicine · doi:10.1080/07853890600622143 · Cited by 85
L-glutamine for sickle cell disease: Knight or pawn?
Sadaf, A., & Quinn, C. T. (2020) · Experimental Biology and Medicine · doi:10.1177/1535370219900637 · Cited by 81
Castiglione, N., Rinaldo, S., Giardina, G., Stelitano, V., & Cutruzzolà, F. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4196 · Cited by 79
“As mentioned above, the reduced NO bioavailability also represents one of the pathological trait of SCD, a genetic disease due to a point mutation of the beta-chain of Hb (227); these patients accumulate huge amounts of free Hb, which reduces NO bioavailability (286, 348).”
Windsant, I. C. V., Wit, N. C. J. D., Sertorio, J. T. C., Beckers, E. A. M., Tanus-Santos, J. E., Jacobs, M. J. H. M., & Buurman, W. A. (2012) · Critical Care · doi:10.1186/cc11359 · Cited by 80
“In line with this finding, increased fHb levels in patients with chronic and acute hemolysis have been associated with decreased NO bioavailability within the microcapillary bed, decreased organ perfusion and increased organ injury [16-18].”
BackgroundMethodSelf-citationCerebrovascular reserve capacity is impaired in patients with sickle cell disease
Nur, E., Kim, Y.-S., Truijen, J., van Beers, E. J., Davis, S. C. A. T., Brandjes, D. P., Biemond, B. J., & van Lieshout, J. J. (2009) · Blood · doi:10.1182/blood-2009-05-223859 · Cited by 79
Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology
Bakeer, N., James, J., Roy, S., Wansapura, J., Shanmukhappa, S. K., Lorenz, J. N., Osinska, H., Backer, K., Huby, A.-C., Shrestha, A., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600311113 · Cited by 79
Yuditskaya, S., Tumblin, A., Hoehn, G. T., Wang, G., Drake, S. K., Xu, X., Ying, S., Chi, A. H., Remaley, A. T., Shen, R.-F., et al. (2009) · Blood · doi:10.1182/blood-2008-03-142604 · Cited by 80
Hypoxia-induced acute lung injury in murine models of sickle cell disease
Pritchard, K. A., Ou, J., Ou, Z., Shi, Y., Franciosi, J. P., Signorino, P. R., Kaul, S., Ackland-Berglund, C. E., Witte, K., Holzhauer, S., et al. (2004) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00288.2002 · Cited by 79
“A possible explanation for this paradoxical increase in cGMP in SCD mice where NO consumption is increased (2, 45) is the fact that guanylyl cyclase can also be activated by compound I, which is formed when hydrogen peroxide reacts with catalase (10, 58).”
BackgroundHemolysis transforms liver macrophages into antiinflammatory erythrophagocytes
Pfefferlé, M., Ingoglia, G., Schaer, C. A., Yalamanoglu, A., Buzzi, R. M., Dubach, I. L., Tan, G., López-Cano, E. Y., Schulthess, N., Hansen, K., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137282 · Cited by 82
Hoppe, C. C., Kuypers, F. A., Larkin, S. K., Hagar, W., Vichinsky, E. P., & Styles, L. A. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08480.x · Cited by 81
Metadata
- Authors
- Reiter, C. D., Wang, X., Tanus-Santos, J. E., Hogg, N., Cannon, R. O., Schechter, A. N., & Gladwin, M. T.
- Affiliations
- National Institutes of Health (US)
- Medical College of Wisconsin (US)
- Corresponding author
- Gladwin, Mark T.
- Venue
- Nature Medicine
- Published
- 2002-11-11
- Volume
- 8
- Issue
- 12
- Pages
- 1383-1389
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4241694836
- Semantic Scholar
- 80bbf9611dbe14c7276b2a4dbca6e42007866746
- Cited by
- 1,330
- References
- 45
- Citations by year
- 2026: 44 · 2025: 39 · 2024: 45 · 2023: 39 · 2022: 57 · 2021: 55 · 2020: 56 · 2019: 59 · 2018: 60 · 2017: 45 · 2016: 62 · 2015: 63 · 2014: 69 · 2013: 68 · 2012: 68
- FWCI
- 20.26
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (GM55792)
- National Center for Research Resources (P41RR001008, RR 01008)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Hemoglobin structure and function
- Health Sciences › Medicine › Physiology (medical) › Nitric Oxide and Endothelin Effects
- Keywords
- free hemoglobin, nitric oxide bioavailability, sickle cell disease, chronic hemolysis, plasma hemoglobin, forearm blood flow, hemoglobin oxidation, vasoconstriction
- MeSH terms
- Adult, Anemia, Sickle Cell, Biological Availability, Heme, Hemocyanins, Hemoglobins, Hemolysis, Humans, Middle Aged, Nitric Oxide, Oxidation-Reduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.